Novel therapeutic strategies for multiple myeloma

Understanding novel therapeutic agents for multiple myeloma.

Multiple myeloma, a B cell malignancy of the plasma cells, remains incurable. Advances in high-dose chemotherapy and stem cell transplantation have improved overall survival and event-free disease periods, but relapses are inevitable. New therapeutic agents have shown promising clinical use in patients with relapsed or refractory multiple myeloma. This article discusses the therapeutic applicat...

Novel therapeutic targets in multiple myeloma.

Multiple myeloma (MM) is a disorder of clonal plasma cells that accumulate in the bone marrow and secrete a monoclonal protein detectable in the blood and/or urine. In the last decade, the outcome of patients with MM has markedly improved owing to the introduction of agents such proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide, lenalidomide) as induction, consolidation...

Novel immunotherapy strategies for multiple myeloma and other haematological malignancies

Ned Tijdschr Klin Chem Labgeneesk 2012, vol. 37, no. 1 22. van der Weide J, Steijns LS, van Weelden MJ, de Haan K. Eerst prikken, dan slikken. Pharmaceutisch Weekblad. 2001; 136: 565-569. 23. www.cypalleles.ki.se. 24. de Vos A, van der Weide J, Loovers HM. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics...

New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.

Multiple myeloma is a B-cell malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Although new therapeutic options introduced in recent years have resulted in improved survival outcomes, multiple myeloma remains incurable for a large number of patients, and new treatment options are urgently needed. Over the last 5 years, there has been a renewed interest in ...

Novel therapies for multiple myeloma